The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Siglecs as Immune Cell Checkpoints in Disease
Abstract
Sialic acid–binding immunoglobulin-type lectins (Siglecs) are expressed on the majority of white blood cells of the immune system and play critical roles in immune cell signaling. Through recognition of sialic acid–containing glycans as ligands, they help the immune system distinguish between self and nonself. Because of their restricted cell type expression and roles as checkpoints in immune cell responses in human diseases such as cancer, asthma, allergy, neurodegeneration, and autoimmune diseases they have gained attention as targets for therapeutic interventions. In this review we describe the Siglec family, its roles in regulation of immune cell signaling, current efforts to define its roles in disease processes, and approaches to target Siglecs for treatment of human disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor cells with abnormal expression of sialic acid upregulate siglec family expression to infiltrate immune cells in the TME.”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [267]
In the citing paper
“The function of inhibitory siglecs closely resembles the PD‐1 immune checkpoint function (Figure 1) [266, 267].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [267]
In the citing paper
“Sialic acid‐binding immunoglobulin‐like lectins (Siglecs) have specific interactions with the immunomodulatory properties of sialoglycans.”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [267]
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · cited 1×
“In the cancer microenvironment the ligand for PD-1 (PD-L1) is upregulated on cancer cells, leading to suppression of antitumor cytotoxic T cells by recruitment of PD-1 to the immunological synapse (181, 183, 184) (Figure 4e).”
BackgroundDoherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075 · cited 1×
“In contrast, however, Siglec-F undergoes endocytosis in a clathrin/dynamin- and caveolin-independentmechanism that is dependent on ADP-ribosylation factor 6 (ARF6), a small GTPase associated with a less-studied endocytic pathway (66, 83, 84).”
BackgroundMacrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528 · cited 3×
“Since sialic acids are ligands for inhibitory Siglecs, there is a direct analogy to PD-1/PD-L1, where sialic acids on cancer cells are ligands that could recruit Siglecs to suppress immune responses (Figure 4e,f ).”
BackgroundChimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031
Self-citationInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
The development of allergic inflammation
Galli, S. J., Tsai, M., & Piliponsky, A. M. (2008) · Nature · doi:10.1038/nature07204 · Cited by 1,839
Research works printed but not linked: 5
- Miles LA, 2019, Science, 19, 110
- Press OW, 1989, Cancer Res, 49, 4906
- Jellusova J, 2011, Front. Immunol., 2, 96
- Hoogeboom R, 2016, Curr. Top. Microbiol. Immunol., 393, 45
- Adams OJ, 2018, Glycobiology, 28, 640
Cited by
Global view of human protein glycosylation pathways and functions
Schjoldager, K. T., Narimatsu, Y., Joshi, H. J., & Clausen, H. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00294-x · Cited by 1,309
Small RNAs are modified with N-glycans and displayed on the surface of living cells
Flynn, R. A., Pedram, K., Malaker, S. A., Batista, P. J., Smith, B. A. H., Johnson, A. G., George, B. M., Majzoub, K., Villalta, P. W., Carette, J. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.023 · Cited by 633
Carbohydrate-Based Macromolecular Biomaterials
Su, L., Feng, Y., Wei, K., Xu, X., Liu, R., & Chen, G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01338 · Cited by 335
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
“Due to its stable expression profile and lack of significant extracellular shedding or internalization properties under physiological conditions, CD22 serves as an attractive target for ADCs [78].”
Metadata
- Authors
- Duan, S., & Paulson, J. C.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Paulson, James C.
- Venue
- Annual Review of Immunology
- Publisher
- Annual Reviews
- Published
- 2020-04-26
- Volume
- 38
- Issue
- 1
- Pages
- 365-395
- ISSN
- 0732-0582 (ISSN-L)
- 1545-3278
- OpenAlex
- W3003215804
- Cited by
- 452
- References
- 223
- Citations by year
- 2026: 56 · 2025: 80 · 2024: 87 · 2023: 61 · 2022: 64 · 2021: 69 · 2020: 35
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL107151)
- National Institute of Allergy and Infectious Diseases (U19AI136443, R01AI132790, R01AI050143)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- Siglecs, immune checkpoint, sialic acid, immune cell signaling, self/non-self discrimination, cancer immunotherapy, asthma, allergy, neurodegeneration, autoimmune disease, therapeutic target
- MeSH terms
- Immune Checkpoint Proteins, Animals, Disease Susceptibility, Humans, Immune System, Lymphocytes, Signal Transduction, Biomarkers, Immunomodulation, Sialic Acid Binding Immunoglobulin-like Lectins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Siglecs as Immune Cell Checkpoints in Disease. https://app.cochat.ai/papers/10.1146/annurev-immunol-102419-035900
- The paper
- Duan, S., & Paulson, J. C. (2020). Siglecs as Immune Cell Checkpoints in Disease. Annual Review of Immunology. https://doi.org/10.1146/annurev-immunol-102419-035900
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.